NKGen Biotech, Inc. to Become Publicly Traded Company via Business Combination with Graf Acquisition Corp. IV
14 avr. 2023 20h19 HE
|
NKGen Biotech
NKGen Biotech, Inc. (“NKGen”), a clinical stage Natural Killer (NK) cell therapy company, has entered into a merger agreement with Graf Acquisition Corp. IV NKGen Biotech, Inc.’s non-genetically...
Global Natural Killer NK Cell Therapy Market Clinical Trials Companies Insight 2023
20 mars 2023 02h22 HE
|
KuicK Research
Delhi, March 20, 2023 (GLOBE NEWSWIRE) -- Global Natural Killer (NK) Cell Therapeutics Market Trends, Companies & Clinical Trials Insight 2023 Report Highlights: Global Natural Killer (NK)...
NKGen Biotech Announces Formation of Scientific Advisory Board to Drive its Pipeline Strategy for Natural Killer Cell Therapies Targeting Neurodegenerative Diseases
08 mars 2023 13h27 HE
|
NKGen Biotech
SANTA ANA, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of natural killer (NK) cell...
NKGen Biotech Appoints Paul Y. Song, MD as Chief Executive Officer
10 janv. 2023 13h27 HE
|
NKGen Biotech
SANTA ANA, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of natural killer cell therapies,...
NKGen Biotech Announces Collaboration with the Parkinson’s Foundation to Bring Its Novel Natural Killer Cell Therapy to the Clinic for Advanced Parkinson’s Disease
04 nov. 2022 12h35 HE
|
NKGen Biotech
SANTA ANA, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc., a biotechnology company harnessing the power of the body’s immune system through the development of natural killer (NK) cell...
NKGen Biotech Receives IND Clearance from FDA for SNK02 Allogeneic Natural Killer Cell Therapy for Solid Tumors
17 oct. 2022 14h27 HE
|
NKGen Biotech
SANTA ANA, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc., a biotechnology company harnessing the power of the body’s immune system through the development of natural killer (NK) cell...
NKGen Biotech Announces Publication in Journal of Cancer Research and Cellular Therapeutics on Durable Response for SNK01 in Advanced Sarcoma
21 sept. 2022 13h09 HE
|
NKGen Biotech
SANTA ANA, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of natural killer cell...
NKGen Biotech to Present at the Baird 2022 Global Healthcare Conference
07 sept. 2022 14h00 HE
|
NKGen Biotech
SANTA ANA, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell...
NKGen Biotech To Present SNK01 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2022
06 sept. 2022 14h37 HE
|
NKGen Biotech
SANTA ANA, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
Alphageneron to Participate in Cell Therapy Durability Response Summit
17 août 2022 10h30 HE
|
Alphageneron Pharmaceuticals
CAMBRIDGE, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Alphageneron Pharmaceuticals, Inc. (“Alphageneron” or the “Company”), a clinical stage pharmaceutical company developing a diverse platform of...